Scott Glenn Joins Exagen Diagnostics as Chairman and CEO Experienced CEO and venture capitalist to provide leadership, accelerate growth and drive value
ALBUQUERQUE, N.M., Dec. 1 /PRNewswire/ -- Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced the appointment of Scott Glenn as chairman of the company's board of directors and chief executive officer.
Prior to joining Exagen, Glenn was managing partner of Windamere Venture Partners and founder of a number of successful biomedical companies including Prometheus Laboratories, Santarus, Dexcom, Somaxon Pharmaceutical and Cadence Pharmaceuticals. In addition, he was a founder at Zogenix, NovaCardia (sold to Merck) and Proprius (sold to Cypress). Prior to Windamere Ventures, he was the president and CEO of Quidel Corporation and before that he held various management positions, including division general manager with Allergan Pharmaceuticals. He serves as a director and founder of Evoke Pharmaceuticals and Planet Biopharmaceuticals.
"I am impressed with Exagen's unique position and approach to managing the massive amounts of genetic information created in the past decade, developing it into superior molecular diagnostics for use in a large number of diseases," said Glenn. Coperna, Exagen's search engine, is differentiated from competing methodologies because it can quickly analyze a broad amount of genomic information and identify statistically significant marker sets without the need for lengthy laboratory testing processes. This results in dramatic "speed to discovery" advantages for Exagen.
Exagen is the emerging leader in laboratory-discovered and developed genomic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the molecular diagnostics industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, visit www.exagen.com.
SOURCE Exagen Diagnostics, Inc.